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Introduction. Chronic obstructive pulmonary disease (COPD) is associated with comorbidities such as cardiovascular disease,
metabolic disease, osteoporosis, and anxiety and/or depression. Although pulmonary rehabilitation programs are proven to be
beneficial in patients with COPD, it is unclear whether comorbidities influence pulmonary rehabilitation outcomes. The aim of
the present review was to investigate to what extent the presence of comorbidities can affect pulmonary rehabilitation outcomes.
Methods. The systematic literature search (Pubmed, EMBASE, and PEDro) resulted in 4 articles meeting the inclusion criteria.
The odds ratios (95% confidence intervals) of the logistic regression analyses, with comorbidities as independent variables and
pulmonary rehabilitation outcomes (dyspnea, functional exercise capacity, and quality of life) as dependent variables, were used for
data extraction. Results. Patients with anxiety and/or depression less likely improve in dyspnea. Osteoporosis is associated with less
improvements in functional exercise capacity, while cardiovascular disease does not seem to negatively impact on this outcome.
Patients with cardiovascular comorbidity will experience less positive changes in quality of life.Conclusion. Evidence from literature
suggests that comorbidities can have a negative influence on pulmonary rehabilitation outcomes. Screening for comorbidities in
pulmonary rehabilitation settings seems useful to readdress the right patients for individually tailored pulmonary rehabilitation.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is often
described as a multicomponent syndrome, characterized by
pulmonary and extrapulmonary consequences [1–3]. The
pulmonary component of the disease is characterized by air-
flow limitation and chronic inflammation and typically gives
rise to symptoms of cough, sputum production, and dyspnea
[2]. The origin of the extrapulmonary consequences or
comorbidities in COPD, which are prevalent alongside the
disease spectrum [3–6], remains unclear. However, a lot of
possible mechanisms have been suggested in literature. Sys-
temic inflammation, inactivity, and deconditioning seem to
have an important role in the development of these comor-
bidities [4, 7]. Cardiovascular disease, metabolic disease,
osteoporosis, and anxiety and/or depression are the most fre-
quently reported [1, 4, 6, 8, 9]. For all these conditions, reha-
bilitation andmore specifically exercise training are indicated
[10]. Pulmonary rehabilitation programs, generally consist-
ing of both exercise training and strength training, are part of
nonpharmacological interventions improving dyspnea, exer-
cise capacity, quality of life, the amount of hospitalizations,
and the recovery afterwards in patients with COPD [11–13].
Comorbidities increase the complexity of individual patients
as evidenced by increased hospital admission rates and mor-
tality [1–3]. It is, hence, plausible that conventional pul-
monary rehabilitation may be more difficult in patients with
comorbidities. On the other hand, the room for improvement
may be larger in patients with COPD and comorbidity [14].
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Literature does not provide clarity about the role of comor-
bidities on the success of pulmonary rehabilitation programs
in patients with COPD. The aim of the present systematic
review was to summarize the relevant literature on this topic,
with the following research question: “Do comorbidities in
COPD have an impact on outcomes of pulmonary rehabilita-
tion programs”?
2. Material and Methods
This systematic review adhered where possible to the
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) statement on developing a systematic
review [15].
2.1. Inclusion Criteria. Studies meeting the following criteria
were included. (1) The study included stable patients with
COPD (GOLDI-IV). (2) The patients with COPD should be
screened in terms of comorbidities before starting pulmonary
rehabilitation or comorbidities should be collected from
medical records. (3) Comorbidities should include cardiovas-
cular disease (ischemic heart disease, heart failure, and hyper-
tension) and/or metabolic disease (diabetes, dyslipidemia,
and obesity) and/or osteoporosis, and/or anxiety and/or
depression. (4)The study predicted the outcomes of standard
outpatient rehabilitation programs, that is, dyspnea, exercise
capacity, or quality of life. Reviews were not selected, but
references were hand-searched for relevant literature.
We did not report muscle weakness as a comorbidity in
the present review as it can be assumed that muscle weakness
ismost likely present in those patients referred for pulmonary
rehabilitation.
2.2. Search Strategy. A systematic electronic literature search
was performed in Pubmed, PEDro (Physiotherapy Evidence
Database), and EMBASE (Excerpta Medica dataBASE). The
search terms we used included COPD, comorbidities or
extrapulmonary comorbidities, and rehabilitation. In PEDro,
the search was performed by indicating COPD, fitness train-
ing, and cardiothoracics in the proposed key terms. A more
detailed description of the search strategies is depicted in
Table 1. Reference manager 11 was applied to combine all the
records from the three databases, to exclude duplicates and to
provide information about the title and abstracts for abstract
screening. The review team consisted of two reviewers (MH
andHVR),who screened the title and abstract of the retrieved
articles. Papers that met all in- and exclusion criteria were
labeled as “1,” other articles were excluded and labeled as “0.”
When disagreement occurred, MH and HVR re-evaluated
the specific records, discussed them, and gave a final score in
consensus. Additional articles were picked up by reviewing
the reference list of relevant articles (hand-search). Arti-
cles which were labeled as “1,” were selected for full text
assessment to check if they met the predetermined in- and
exclusion criteria.
2.3. Data Extraction. From each article, we extracted the
study design, the type of analysis and the disease severity.
Table 1: Search strategy for the three different electronic databases.
Pubmed
(((((COPD) OR Chronic Obstructive Pulmonary
Disease) OR Chronic Obstructive Pulmonary Disease
[MeSH Terms])) AND (((Comorbidities) OR
(Co-morbidities) OR Extrapulmonary comorbidities))
AND ((Rehabilitation) OR Rehabilitation [MeSH
Terms]))
PEDro ((COPD) AND (Fitness training) AND(Cardiothoracics))
EMBASE
((“COPD” exp OR COPD) AND ((“Comorbidities”)
OR (“Co-morbidities”) OR “extrapulmonary
Comorbidities”) AND (“Rehabilitation” exp OR
Rehabilitation))
The content of the rehabilitation program described in each
article was used. The specific comorbidities, their prevalence
and the outcomes of pulmonary rehabilitation were extracted
and the odds ratio (95% confidence interval (CI)) from
each logistic regression analysis was retrieved to investigate
the impact of comorbidities on outcomes of pulmonary
rehabilitation. If the odds ratio was not calculated, but the
author did report the 𝛽-coefficient (standard error (SE)) from
the logistic regression analysis, we calculated the odds ratio
(OR) with the formula: OR = 𝑒𝛽. The lower limit of the 95%
CI of the odds ratio was then found based on 𝛽 − 1.96 ∗ SE
and the upper limit of the 95% CI based on 𝛽 + 1.96 ∗ SE.
When only the 𝛽-coefficient without SE was presented, the
author was contacted to become the 95% CI of the OR. A
significant OR < 1 indicates that the presence of the specific
comorbidity leads to a lower chance of improving in the out-
come investigated.With a significant OR being higher than 1,
it is more likely that the presence of the comorbidity leads to
improvement in the outcome of pulmonary rehabilitation.
3. Results
The systematic review resulted in 4 articles, involving a total
of 3595 stable patients with COPD. The majority of patients
(𝑛 = 2962) came from one study [16]. The flow chart of
the results of the search strategies and the study selection
are shown in Figure 1. Comorbidities were either retrieved
from the medical record of the patients [16, 17] or were
identified based on the Charlson Comorbidity Index [16,
18–20]. All articles reported comorbidities to be prevalent
among patients with COPD, with a mean percentage of 70%
of patients having one or more comorbidities. Pulmonary
rehabilitation programs were supervised and involved either
strength training or both strength and whole body exercise
training. In 2 out of 4 articles, pulmonary rehabilitation
programsweremultidisciplinary [17, 18]. One article reported
patients to be referred to standard outpatient rehabilitation,
with no detailed description of the program [20]. None of
the articles provided a description of the modifications of
the goals of the program or the program content, taking into
account the specific comorbidities. The pulmonary rehabil-
itation programs were beneficial in both patients with and
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Search databases
Relevant articles 
from reference list 
(hand-searching)
Studies identified from database searching
Titles and abstracts studies screened for
eligibility
Full text studies and screened for eligibility
Studies included in the systematic review
Excluded duplicates
∙ (Systematic) review
∙ No stable patients with
COPD
∙ No comorbidities at
baseline
∙ No standard pulmonary
rehabilitation program or
rehabilitation
∙ Different outcomes of
pulmonary rehabilitation
∙ Not available in Englishn = 4
n = 138
n = 3
n = 703
n = 565
n = 16
Pubmed n = 222
PEDro n = 233
EMBASE n = 248 Excluded n = 549
Figure 1: Flow chart of the results of the search strategies and study selection.
without comorbidities. However, the improvements in dys-
pnea and health status were significantly less in patients with
comorbidities, with patients diagnosedwithmore comorbidi-
ties achieving the least improvements [16]. Details about the
comorbidities, the content of the pulmonary rehabilitation
programs, the specific outcomes, and the response rates of the
included articles can be found in Table 2. Table 3 provides an
overview of the obtained odds ratios (95% CIs) of the logistic
regression analyses. More specifically, we concluded that
patients with COPD and anxiety and/or depression have a 10
times higher chance of not reaching the minimal clinically
important difference (MCID) in symptoms of dyspnea [17].
On the other hand, Crisafulli et al. [16] showed that having
metabolic disease is associated with a higher chance of
improving the symptoms of dyspnea and that osteoporosis is
associated with a lower chance of improving the symptoms
of dyspnea. However, these results were not significant.
Improvements in functional exercise capacity were 4 times
lower in patients with osteoporosis [18] and 2 times higher
in patients with cardiovascular disease [16]. There was no
consistency regarding the association betweenmetabolic dis-
ease and functional exercise capacity, since 3 studies showed
different results [16, 17, 20]. Patients with cardiovascular and
metabolic disease will improve less in terms of quality of life
[16, 17].The relation betweenmetabolic disease and quality of
life did not show significance, while the association between
cardiovascular disease and quality of life was found to be
significant in the 2 studies [16, 17].
4. Discussion
The primary aim of our review was to summarize the litera-
ture concerning the impact of comorbidities on the outcomes
of pulmonary rehabilitation. We found that the presence of
comorbidities can have a negative influence on some out-
comes of pulmonary rehabilitation. Overall, however, data
are scarce. In detail, our review indicated that patients with
symptoms of anxiety and/or depression are less likely to
improve in dyspnea. In addition, patients with osteoporosis
were found to improve less in terms of functional exercise
capacity and patients with cardiovascular disease to improve
more in functional exercise capacity. The findings on
metabolic disease were inconsistent. Lastly, we found less
positive changes in quality of life in patients with cardiovas-
cular disease. A formal meta-analysis was not possible due to
heterogeneity of the methods and the outcomes.
The present study contains several limitations. First of
all, the majority of studies were retrospective, which could
have impacted on the accuracy of collecting comorbidi-
ties. Another limitation was that we only included studies
reporting odds ratios to show associations and studies pro-
viding data on improvements in pulmonary rehabilitation
outcomes. Therefore, studies looking at comorbidities and
outcomes in a differentwaywere notwithheld [19, 21–25].The
study of von Leupoldt et al. [25] confirmed our findings that
anxiety and/or depression are associated with more symp-
toms of dyspnea. They showed that anxiety was positively
associated with symptoms of dyspnea at rest (𝛽 = 0.18;
𝑃 < 0.01), measured by the Borg scale before performing
a 6MWD test. Both anxiety and depression were associated
with more symptoms of dyspnea at baseline, measured by
the Baseline Dyspnea Index (𝛽anxiety = −0.25; 𝑃 < 0.001;
𝛽depression = −0.35;𝑃 < 0.001) and after the 6MWD (𝛽anxiety =
0.15; 𝑃 < 0.05; 𝛽depression = 0.22; 𝑃 < 0.05). Vanfleteren and
colleagues [19] rejected the fact that cardiovascular disease is
associated with higher levels of functional exercise capacity,
by showing a negative association between ischemic heart
disease and 6MWD (𝛽 = −0.11; 𝑃 = 0.007). Mentz et al.
[21] were not able to show significant different associations
between either patients suffering fromcardiovascular disease,
that is, heart failure and COPD, or patients only diagnosed
with COPD and outcomes of pulmonary rehabilitation. Trap-
penburg et al. [24] focused on maximal work rate, functional
exercise capacity, and quality of life as dependent variables.
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Table 3: Overview of the logistic regression analyses performed in each article.
Comorbidity Author Outcome variables of PR Measurement OR (95% CI) 𝑃 value
Anxiety and/or
depression Carreiro et al. [17]
Improvement in dyspnea
(defined as +1 point) MDI 0.10 (0.02 to 0.58) 0.01
Osteoporosis
Crisafulli et al. [16] Improvement in dyspnea(defined as −1 point) MRC 0.69 (0.66 to 1.48) 0.07
Crisafulli et al. [18]
Improvement in functional
exercise capacity
(defined as +54 meter)
6MWD 0.28 (0.11 to 0.70) <0.01
Cardiovascular disease
Crisafulli et al. [16]
Improvement in functional
exercise capacity
(defined as +54 meter)
6MWD 2.36 (1.85 to 3.01) 0.001
Carreiro et al. [17]
Improvement in quality of
life
(defined as −4 points)
SGRQ 0.20 (0.05 to 0.85) 0.03
Crisafulli et al. [16]
Improvement in quality of
life
(defined as −4 points)
SGRQ 0.67 (0.55 to 0.83) 0.001
Metabolic disease
Crisafulli et al. [16] Improvement in dyspnea(defined as −1 point) MRC 1.17 (0.93 to 1.77) 0.10
Carreiro et al. [17]
Improvement in functional
exercise capacity
(defined as +30 meter)
6MWD 4.57 (0.91 to 23.0) 0.07
Crisafulli et al. [16]
Improvement in functional
exercise capacity
(defined as +54 meter)
6MWD 0.57 (0.49 to 0.67) 0.001
Walsh et al. [20]
Improvement in functional
exercise capacity
(defined as +60.9 meter)
6MWD 2.47 (1.08 to 5.67) 0.03
Crisafulli et al. [16]
Improvement in quality of
life
(defined as −4 points)
SGRQ 0.91 (0.77 to 1.07) 0.25
Cardiovascular disease (ischemic heart disease, heart failure, and hypertension); metabolic disease (diabetes, dyslipidemia, and obesity); bone disease
(osteopenia, osteoporosis); MDI: Mahler Dyspnea Index; MRC: Medical Research Council Scale; 6MWD: six-minute walking distance; SGRQ: St George’s
Respiratory Questionnaire.
represents significant positive associations; represents significant negative associations; represents nonsignificant positive associations;
represents nonsignificant negative associations.
Only the association between maximal work rate and symp-
toms of depression was significant, meaning that patients
with COPD and depressive symptoms improve less in max-
imal work rate (𝑟 = −0.34; 𝑃 = 0.008). The present review
could not draw clear conclusions about the influence of
metabolic disease on functional exercise capacity. However,
Sava et al. [23] focused on obesity (BMI> 30 kg/m2) as a com-
ponent of the metabolic disease and looked at its influence
on the change in the 6MWD test. More specifically, they con-
cluded that obese patients with COPD significantly improved
in functional exercise capacity, but to the same extent as
overweight patients and persons with a normal BMI. These
findings are in line with the conclusions of Walsh et al. [20].
In another study on obesity, Ramachandran and colleagues
[22] revealed that symptoms of dyspnea, investigated by
the Chronic Respiratory Disease Questionnaire, were higher
after pulmonary rehabilitation in patients with a BMI >
30 kg/m2. In contrast, Crisafulli et al. [16] found patients with
metabolic disease to have a higher chance of improving in
symptoms of dyspnea, but these results were not significant.
The last limitation was that the rehabilitation programs in
the included studies were not adapted to the specific comor-
bidities. It remains unknown whether better adaptations of
the rehabilitation programs to the comorbidities would have
resulted in better outcomes.
Focusing on comorbidities in patients with COPD is of
importance since they contribute to the overall severity of the
disease and have a negative impact on patient’s life expectancy
[12, 26]. Considering this, there is an urgent need to address
the role of comorbidities into the nonpharmacological treat-
ment of patients with COPD. Although pulmonary rehabili-
tation programs are promoted by international guidelines to
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be an integral part of the management of COPD [11, 27], they
largely focus on single diseases and do not take into account
the comorbidities. Therefore, one must strive to develop
guidelines for rehabilitation focusing on patients not on dis-
eases so that treatment is in the individual’s best interests [28].
Boyd et al. [29] confirm that comorbidities should receive
more attention in patients with chronic diseases. In up to 55%
of clinical trials in patients with COPD, patients with comor-
bidities are excluded [29]. This may explain why we only
found 4 articles meeting our in-and exclusion criteria. Our
findings can be supported by Patrick et al. [30], who investi-
gated the effects of medical comorbidities on rehabilitation in
geriatric patients. The focus of rehabilitation in the elderly
addressed restoring functional independence and optimizing
quality of life. They concluded that disability and cardiovas-
cular, gastrointestinal, musculoskeletal, and endocrinal dis-
ease were significant negative predictors of rehabilitation effi-
ciency in geriatric patients. On the other hand, not referring
patients with comorbidities to pulmonary rehabilitation is
surely not theway forward. All studies included in the current
review demonstrate that patients with comorbidities can be
trained with significant benefits.The real question is whether
programs specifically tailored on comorbidities can improve
these outcomes. Standard outpatient programs normally
include exercise training as one of the most important com-
ponents, which is proven to have a positive effect on cardio-
vascular disease, metabolic disease, and osteoporosis [26]. In
order to achieve these benefits, patients with COPD have to
train for 8–12 weeks, four times a week, at an intensity of
60–80% of maximal workload, during 20–30 minutes each
session [31–33]. Based on the joint statement of the European
Association for Cardiovascular Prevention and Rehabilita-
tion, patients with ischemic heart disease and heart failure
benefit from training sessions ranging from light (25–44%
peak VO2, continuous training) to moderate (45–59% peak
VO2, continuous training) to high (60–84% peak VO2, inter-
val training) to very high intensity (≥85% peak VO2, interval
training) to improve exercise capacity. The chosen intensity
depends on the preserved ejection fraction and the exercise
capacity of the patient during the pretraining period, mea-
sured by a cardiopulmonary exercise test [34]. Patients with
arterial hypertension are instructed to train 30 minutes at
moderate intensity (40–60%HRR), 5 times a week or 20min-
utes at vigorous intensity (60–84%HRR), 3 times a week [35].
The guideline for patients with metabolic disease contains
that patients have to perform 150 minutes of aerobic exercise,
three times a week atmoderate to vigorous intensity (40–60%
VO2max) [35, 36]. Literature is available on the importance
of exercise training in patients with osteoporosis. However,
there is no clarity about the duration, intensity, or frequency
of the training programs [37]. For patients with anxiety
and/or depression, the advice is to train 3-4 times a week at
moderate intensity (40% VO2max), during sessions of 20–
30 minutes for a period of 8–14 weeks [38]. According to
Fischer et al. [39] the intensity of the program being too high
is themost often reported reason for drop-out in patientswith
COPD. In some patients, therefore, the guidance on training
for comorbidities can overrule the guidance for training of
the COPD related patients. A last point of attention relates to
self-management as part of the disease management, which
aims at changing the behavior of the patient by improving
their problem solving skills. Clearly, these also need to be
adapted to the comorbidities [40]. These literature findings
defend our statement that comorbidities should be included
into themanagement of patients with COPD, but that there is
a need for cross-disease guidelines for rehabilitation. Training
programs should be individually tailored and adapted to the
specific comorbidity(ies) of the patient.
5. Conclusions
Comorbidities are prevalent in patients with COPD and
they potentially have a negative effect on outcomes of stan-
dard pulmonary rehabilitation. More specifically, they could
reduce the benefits in terms of dyspnea, functional exercise
capacity, and quality of life. Based on the present review,
we conclude that including patients with comorbidities in
pulmonary rehabilitation programs is still reasonable as they
improve with training. However, we should be aware that,
without altering the program, response rates will be lower. An
optimal treatment should therefore include a baseline assess-
ment of comorbidities with a subsequent individually tailored
pulmonary rehabilitation program.
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